Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$27.62-6.05%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · AMLX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -39.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
AMLX — litigation filed
Dated 2026-09-08
Entry into a Material Definitive Agreement. On September 8, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) entered into a Manufacturing and Supply Agreement (the “Bachem Manufacturing Agreement”) with Bachem Americas, Inc. (“Bachem”) and on September 1, 2026, the Company entered into a term sheet (the “Polypeptide Term Sheet”) with Polypeptide Group AG (“Polypeptide”), pursuant to which Bachem and Polypeptide, respectively, will manufacture and supply the Company’s long-term supply requir…
Why it matters: The filing is the next step after LUCIDITY met its main and all secondary goals. A delay could push back the review and launch plan.
Supportive ifAmylyx submits the avexitide NDA to the FDA by December 31, 2026.
Worry ifAmylyx misses its year-end filing plan or reports a major issue that delays the NDA.
Why it matters: The next dose groups test whether AMX0114 can advance beyond the lowest dose. Serious safety problems could slow or stop the trial.
Watch forAmylyx reports that Cohorts 2 and 3 have no drug-related serious harms as dosing moves to 50 mg.
Also watch forAmylyx reports a drug-related serious harm, pauses dosing, or stops the AMX0114 trial.
Why it matters: An IND filing would move Amylyx's long-acting PBH drug into human testing. A delay would slow this pipeline program.
Supportive ifAmylyx files an IND for AMX0318 with the FDA during 2027.
Worry ifAmylyx delays its 2027 filing target or reports that work needed before an IND has stopped.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$205 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $556 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,359 loss on $10,000 · 33.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.